
David A Russler-Germain

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7664352/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Idecabtagene vicleucel: questions regarding the appropriate role and cost. British Journal of Haematology, 2022, 196, .	2.5	3
2	Increased early mortality after fludarabine and melphalan conditioning with peripheral blood grafts in haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide. Leukemia and Lymphoma, 2022, 63, 222-226.	1.3	0
3	Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia. Science Translational Medicine, 2022, 14, eabm1375.	12.4	49
4	Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant. Blood, 2022, 139, 1670-1683.	1.4	57
5	A forgotten friend: CCNU as palliative monotherapy in relapsed Hodgkin lymphoma. Leukemia and Lymphoma, 2021, 62, 486-488.	1.3	1
6	Memory-like Differentiation Enhances NK Cell Responses to Melanoma. Clinical Cancer Research, 2021, 27, 4859-4869.	7.0	33
7	A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy. Cancer Immunology Research, 2021, 9, 1071-1087.	3.4	36
8	Predictors of Relapse and Survival Following Autologous Stem Cell Transplant in Patients with Diffuse Large B-Cell Lymphoma. Blood, 2021, 138, 1832-1832.	1.4	0
9	Eomes and T-Bet Expression Are Required By Mature Primary Human NK Cells for Anti-Leukemia Responses In Vivo. Blood, 2021, 138, 194-194.	1.4	0
10	Cytokine-Induced Memory-like NK Cells Have a Distinct Single Cell Transcriptional Profile and Persist for Months in Adult and Pediatric Leukemia Patients after Adoptive Transfer. Blood, 2021, 138, 3825-3825.	1.4	1
11	Increased Early Mortality after Fludarabine and Melphalan Conditioning with Peripheral Blood Grafts in Haploidentical SCT with Post-Transplant Cyclophosphamide. Blood, 2019, 134, 4496-4496.	1.4	2
12	CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression. Cell, 2017, 168, 801-816.e13.	28.9	177
13	Haploinsufficiency for DNA methyltransferase 3A predisposes hematopoietic cells to myeloid malignancies. Journal of Clinical Investigation, 2017, 127, 3657-3674.	8.2	80
14	Registered report: IDH mutation impairs histone demethylation and results in a block to cell differentiation. ELife, 2016, 5, e10860.	6.0	10
15	DNMT3A-Dependent DNA Methylation May Act As a Tumor Suppressor-Not a Tumor Promoter-during AML Progression. Blood, 2016, 128, 1050-1050.	1.4	3
16	PML-RARA requires DNA methyltransferase 3A to initiate acute promyelocytic leukemia. Journal of Clinical Investigation, 2015, 126, 85-98.	8.2	36
17	The R882H DNMT3A Mutation Associated with AML Dominantly Inhibits Wild-Type DNMT3A by Blocking Its Ability to Form Active Tetramers. Cancer Cell, 2014, 25, 442-454.	16.8	374
18	Whole-Genome Bisulfite Sequencing of Primary AML Cells with the DNMT3A R882H Mutation Identifies Regions of Focal Hypomethylation That Are Associated with Open Chromatin. Blood, 2014, 124, 608-608.	1.4	3

#	Article	IF	CITATIONS
19	R882H DNMT3A Causes Dominant-Negative Inhibition Of WT DNMT3A. Blood, 2013, 122, 3812-3812.	1.4	Ο
20	Frontline polatuzumab vedotin for diffuse large B ell lymphoma: A survey of clinician impressions. EJHaem, 0, , .	1.0	3